The Food and Drug Administration has rejected an application to expand the use of rheumatoid arthritis treatment Rituxan for patients with earlier stages of the disease, biotech drug developers Genentech Inc. and Biogen Idec said Saturday.
FDA nixes wider use of rheumatoid arthritis drugCourtesy Newsvine - business Sat, 10/17/2009 - 09:52
The Food and Drug Administration has rejected an application to expand the use of rheumatoid arthritis treatment Rituxan for patients with earlier stages of the disease, biotech drug developers Genentech Inc. and Biogen Idec said Saturday. Related itemsFDA clears Genentech drug for kidney cancer
FDA prepares to reassess much-debated knee implant
FDA asks for risk plan info on diabetes drug
Canon CanoScan 4400F Color Image Scanner (1306B002)
Plantronics Convert Hands Free Headset with Noise...
|
Popular by tags WeekMonth |
Post new comment